About: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.40 (-4.09%)
NRSNNASDAQNeurosense Therapeutics Ltd
Neurosense Therapeutics Ltd share price
NRSN price activity
Último preço
$ 0,400
Variação (24h)
-0,02 USD (-4,09%)
Volume
212.57K
Volume (média 4 sem.)
-
Abertura
$ 0,43
Variação do dia
$ 0,40 - $ 0,45
Fechamento anterior
$ 0,42
Último negócio
09 Sep, 8:26 pm GMT+0
Atrasado
09 Sep, 8:26 pm GMT+0
NRSN price performance
Atrasado
09 Sep, 8:26 pm GMT+0
quote.marketSignals